ciprofibrate has been researched along with Obesity in 5 studies
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the present study the influence of a four-week daily oral administration of 2 mg/kg body weight ciprofibrate (CAS 52214-84-3) or of 100 mg/kg body weight clofibric acid (CAS 882-09-7) was compared to that of the respective doses of their newly synthesized glycine conjugates in adult male lean and obese Zucker rats." | 3.74 | Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats. ( Deufel, T; Fleck, C; Karge, E; Lupp, A; Oelschlägers, H, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lupp, A | 1 |
| Karge, E | 1 |
| Deufel, T | 1 |
| Oelschlägers, H | 1 |
| Fleck, C | 1 |
| Caira, F | 2 |
| Pacot, C | 2 |
| Bardot, O | 1 |
| Cherkaoui Malki, M | 2 |
| Latruffe, N | 1 |
| Petit, M | 1 |
| Rollin, M | 1 |
| Behechti, N | 1 |
| Grégoire, S | 1 |
| Cavatz, C | 1 |
| Moisant, M | 1 |
| Moreau, C | 1 |
| Silva, JM | 1 |
| Serra e Silva, P | 1 |
| Herbert, JM | 1 |
| Bernat, A | 1 |
| Chatenet-Duchène, L | 1 |
1 trial available for ciprofibrate and Obesity
| Article | Year |
|---|---|
Does obesity influence ciprofibrate activity?
Topics: Adult; Aged; Body Mass Index; Clofibric Acid; Female; Fibric Acids; Humans; Hypolipidemic Agents; Ma | 1998 |
4 other studies available for ciprofibrate and Obesity
| Article | Year |
|---|---|
Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats.
Topics: Animals; Body Weight; Chemical and Drug Induced Liver Injury; Clofibric Acid; Cytochrome P-450 Enzym | 2008 |
Transcriptional and post-transcriptional analysis of peroxisomal protein encoding genes from rat treated with an hypolipemic agent, ciprofibrate. Effect of an intermittent treatment and influence of obesity.
Topics: Acyl-CoA Oxidase; Animals; Clofibric Acid; Fibric Acids; Liver; Male; Microbodies; Obesity; Oxidored | 1995 |
Response of genetically obese Zucker rats to ciprofibrate, a hypolipidemic agent, with peroxisome proliferation activity as compared to Zucker lean and Sprague-Dawley rats.
Topics: Animals; Cholesterol; Clofibric Acid; Cytochrome P-450 Enzyme System; Enzyme Induction; Fibric Acids | 1993 |
Effect of ciprofibrate on fibrinogen synthesis in vitro on hepatoma cells and in vivo in genetically obese Zucker rats.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Clofibric Acid; Dose-Response Relationshi | 1999 |